Phase III Study Seeks to Boost Kiacta's Prospects
By Marie Powers
Thursday, December 16, 2010
Despite a bumpy road that includes two FDA approvable letters, the amyloid A (AA) amyloidosis drug candidate Kiacta (eprodisate) has been given another chance to prove itself through a confirmatory Phase III study that was initiated this week by Bellus Health, of Laval, Quebec, and its development partner Celtic Therapeutics LLLP.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.